How Does Avanos Company Work and What Drives Its Business Model?

Avanos Medical sells enteral feeding systems and non-opioid pain-management platforms. Key products include the MIC-KEY enteral feeding tube (global leader for long-term nutrition) and Pain Management systems such as the ON-Q surgical pain pump and COOLIEF radiofrequency ablation for chronic knee and hip pain.

Buyers are hospitals, long-term care facilities, outpatient surgical centers, and home-health providers; procurement is via hospital supply chains, group purchasing organizations (GPOs), and direct sales teams supported by distributor partnerships.

Customers get reduced length of stay, lower opioid use, and predictable procedure workflows; recurring consumables and disposables drive clinical continuity and permit measurable cost-per-case reductions for providers.

Avanos business model centers on selling capital or durable devices at modest margins and capturing recurring, high-margin consumable revenue – feeding tubes, pump kits, RF cartridges – thus creating annuity-like Avanos revenue streams; clinical data and reimbursement coverage strengthen purchasing pull.

Avanos company derives most revenue from single-use kits and replacement tubes sold into COOLIEF and ON-Q installed bases; over 75 percent of total revenue is recurring consumables, making the razor-and-blade model central to the Avanos business model.

Initial sales of COOLIEF generators or ON-Q pump systems are lower-margin but create installed bases that generate follow-on consumable purchases and service revenue across the Avanos product portfolio.

Avanos monetizes through direct device sales, recurring consumable sales, and multi-year contracts with GPOs and IDNs; these agreements lock pricing and volumes, supporting predictable revenue recognition and margin stability.

Digestive Health drives roughly 60 percent of revenue as of early 2026, while Pain Management supplies the remaining 40 percent; recurring demand in chronic care and a clinical shift away from opioids are the main growth levers for Avanos Medical.

Avanos company captures dominant share in enteral feeding via the MIC-KEY franchise, producing steady consumable-led revenue and recurring demand; this creates a durable revenue stream and high customer retention. The secular move to non-opioid pain management expands market opportunity in chronic pain, supporting Avanos Medical's growth strategy and potential cross-sell.

Strong physician loyalty and high switching costs around enteral feeding devices and disposables act as a moat, while national distribution channels and hospital relationships support scale in the Avanos product portfolio. Manufacturing footprint and supply-chain relationships enable margin recovery after the respiratory divestiture; adjusted EBITDA margins improved to about 22 percent in fiscal 2025/2026.

Avanos revenue streams remain concentrated in hospital settings, so elective procedure volumes and payer reimbursement rates (Medicare/private insurers) materially affect top-line and pricing power. The firm also depends on executing M&A to bolster the chronic pain portfolio; failure raises competitive risk versus larger medtech peers. Supply disruptions or regulatory setbacks would compress margins quickly.

As of fiscal 2025, Avanos Medical has become leaner and more profitable after divesting lower-margin respiratory assets, with adjusted EBITDA near 22 percent, improving from mid-teens previously; this signals improved operational resilience. Long-term valuation still hinges on accelerating organic growth in chronic pain and maintaining payer access; absent sustained growth, the model is exposed to pricing and competitive pressures. See further context in Ownership and Control of Avanos Company